CIT

Across TCGA pan-cancer cohorts, CIT RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CIT data layer compared with 11 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CIT RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CIT expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

MESO, ACC, and LIHC are the cancer types where CIT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.239	0.513	<.001	126	view →
ACC	DFS	Median	All	0.217	0.661	<.001	113	view →
LIHC	DFS	Median	All	0.431	0.649	<.001	105	view →
KIRC	DFS	Tertile	All	0.699	0.516	.001	93	view →
UVM	DFS	Tertile	All	0.265	0.746	<.001	63	view →
PAAD	OS	Tertile	All	0.472	0.821	<.001	54	view →
UCEC	DFS	Tertile	All	0.782	0.883	.002	28	view →
SKCM	DFS	Tertile	II,III,IV	0.413	0.689	.001	25	view →
UCS	OS	Tertile	III,IV	0.637	0.211	.022	24	view →
BLCA	DFS	Tertile	All	0.417	0.651	.009	19	view →
CESC	DFS	Quartile	III,IV	0.368	0.829	.029	14	view →
SARC	OS	Median	All	0.436	0.722	.006	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CIT–MESO (OS)

Open the MESO breakdown →